ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 54.65 M

ABL Bio Inc. Cash and Short-Term Investments is USD 54.65 M for the year ending December 31, 2023, a -11.65% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

ABL Bio Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 61.86 M, a 69.34% change year over year.
ABL Bio Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 36.53 M, a -43.47% change year over year.
ABL Bio Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 64.62 M, a -43.76% change year over year.
ABL Bio Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 114.89 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years